The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CVSI | -14.22% | -92.02% | -39.68% | -93% |
| S&P | +14.5% | +93.32% | +14.09% | +445% |
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the following segments: Consumer Products and Specialty Pharmaceutical. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand. The Specialty Pharmaceutical segment focuses on developing cannabinoids to treat medical indications. The company was founded by H. J. Cole, Michael J. Mona, Jr. and Michael J. Mona III on December 9, 2010 and is headquartered in San Diego, CA.
While most pot stocks fell by a double-digit percentage last month, these nine catapulted higher by at least 16%.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $3.62M | -8.4% |
| Gross Profit | $1.84M | -0.9% |
| Gross Margin | 50.94% | 3.9% |
| Market Cap | $6.82M | -28.6% |
| Market Cap / Employee | $0.14M | 0.0% |
| Employees | 49 | 14.0% |
| Net Income | -$0.26M | 55.3% |
| EBITDA | -$0.07M | 85.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.89M | 85.7% |
| Accounts Receivable | $0.55M | -14.7% |
| Inventory | 4.2 | -19.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.44M | 88.0% |
| Short Term Debt | $1.26M | 379.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -18.44% | 8.5% |
| Return On Invested Capital | 158.04% | -17.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.24M | 517.5% |
| Operating Free Cash Flow | $0.29M | 603.5% |
| Metric | Q4 2023 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 1.70 | - | |||
| Price to Book | 3.32 | 2.84 | 3.33 | 3.60 | -10.89% |
| Price to Sales | 0.54 | 0.40 | 0.39 | 0.46 | -28.48% |
| Price to Tangible Book Value | 4.98 | 4.89 | 8.17 | 8.38 | 70.95% |
| Price to Free Cash Flow TTM | 2.54 | 8.80 | - | ||
| Enterprise Value to EBITDA | -34.12 | -11.91 | -15.57 | -104.54 | 424.51% |
| Free Cash Flow Yield | 39.4% | 11.4% | - | ||
| Return on Equity | -89.5% | -101.9% | -88.2% | -72.0% | -8.83% |
| Total Debt | $0.84M | $0.78M | $1.52M | $1.70M | 242.74% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
